Universal Influenza Vaccine

About Gylden Pharma

Gylden Pharma, formerly known as Emergex, is a private biotechnology company advancing a novel platform of T cell-priming vaccines. Its technology combines immunoproteomics, a nanocluster delivery system, and a microneedle array patch to target conserved viral peptides, aiming for broad, variant-resistant, and durable immunity. The company's lead candidate for Betacoronaviruses has been selected for NIH/NIAID Project NextGen clinical trials, positioning it in the next-generation vaccine landscape against pandemic threats. With in-house GMP manufacturing and a clear focus on infectious diseases, Gylden is targeting some of the world's most pressing immunological challenges.

About Calder Biosciences

Calder Biosciences is a private, preclinical-stage biotech applying its novel 3D-Vaxlock™ protein engineering platform to develop best-in-class vaccines. The platform introduces targeted, covalent dityrosine crosslinks to 'lock' viral immunogens in their most potent prefusion shape, aiming to elicit stronger and more protective immune responses. Initial pipeline targets include RSV and a universal influenza vaccine, with the goal of improving efficacy, durability, and thermostability over existing options. The company emphasizes a de-risked approach by engineering solutions for well-characterized viral targets rather than pursuing de novo discovery.

About Orlance

Orlance is advancing the MACH-1 platform, a needle-free gene gun technology that delivers powdered DNA or RNA vaccines directly into the epidermis, aiming to reduce doses by up to 90% and eliminate cold chain requirements. The company has secured significant non-dilutive funding, primarily from NIH SBIR grants totaling over $16.8M, to progress its pipeline toward Phase 1 trials. With a lead universal flu vaccine at the pre-IND stage, Orlance is preparing for a $12M Series A round in 2026 and is actively seeking development partners to expand its portfolio of vaccine and immunotherapy assets.

About Sinovac Biotech

Sinovac Biotech's mission is to supply vaccines to eliminate human infectious diseases worldwide. Its key achievement was the development and global distribution of CoronaVac, one of the most widely administered COVID-19 vaccines, which solidified its international standing and showcased its integrated manufacturing model. The company's strategy is anchored in its core inactivated vaccine technology platform, with a focus on expanding its pipeline for both endemic and pandemic threats while pursuing commercial partnerships in emerging markets. Financially, it faces the challenge of transitioning from peak pandemic revenue to a sustainable portfolio-driven growth model.

Therapeutic Areas